Design Therapeutics, Inc.
US ˙ NasdaqGS ˙ US25056L1035

SecurityDSGN / Design Therapeutics, Inc.
InstitutionMorgan Stanley
Latest Disclosed Ownership656,565 shares
Latest Disclosed Value $ 6,985,852
Morgan Stanley reports 6.51% decrease in ownership of DSGN / Design Therapeutics, Inc.

On May 15, 2026 - Morgan Stanley filed a 13F-HR form disclosing ownership of 656,565 shares of Design Therapeutics, Inc. (US:DSGN) valued at $6,985,852 USD as of March 31, 2026. The entity filed a previous 13F-HR/A on May 27, 2026 disclosing 702,306 shares of Design Therapeutics, Inc.. This represents a change in shares of -6.51% during the quarter. The current value of the position is $7,064,639 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F DESIGN THERAPEUTICS COM 25056L103 656,565 -45,741 -6.51 6,986 6.04 0.0004
2026-05-27 2025-12-31 13F/A-1 DESIGN THERAPEUTICS COM 25056L103 702,306 526,315 299.06 6,588 397.13 0.0004
2026-02-13 2025-12-31 13F DESIGN THERAPEUTICS COM 25056L103 702,306 526,315 6,588 0.0004
2026-05-27 2025-09-30 13F/A-1 DESIGN THERAPEUTICS COM 25056L103 175,991 -37,559 -17.59 1,325 84.28 0.0001
2025-11-14 2025-09-30 13F DESIGN THERAPEUTICS COM 25056L103 175,991 -37,559 1,325 0.0001
2025-08-15 2025-06-30 13F DESIGN THERAPEUTICS COM 25056L103 213,550 -34,328 -13.85 720 -24.79 0.0000
2025-05-15 2025-03-31 13F DESIGN THERAPEUTICS COM 25056L103 247,878 -98,305 -28.40 957 -55.22 0.0001
2025-05-15 2024-12-31 13F/A-1 DESIGN THERAPEUTICS COM 25056L103 346,183 -82,615 -19.27 2,136 -7.42 0.0001
2025-02-14 2024-12-31 13F DESIGN THERAPEUTICS COM 25056L103 346,183 -82,615 2,136 0.0001
2025-05-14 2024-09-30 13F/A-2 DESIGN THERAPEUTICS COM 25056L103 428,798 39,361 10.11 2,307 76.84 0.0002
2025-02-14 2024-09-30 13F/A-1 DESIGN THERAPEUTICS COM 25056L103 428,798 39,361 2,307 0.0002
2024-11-14 2024-09-30 13F DESIGN THERAPEUTICS COM 25056L103 428,798 39,361 2,307 0.0000
2025-05-14 2024-06-30 13F/A-2 DESIGN THERAPEUTICS COM 25056L103 389,437 -88,655 -18.54 1,305 -32.29 0.0001
2024-10-17 2024-06-30 13F/A-1 DESIGN THERAPEUTICS COM 25056L103 389,437 -88,655 1,305 0.0001
2024-08-14 2024-06-30 13F DESIGN THERAPEUTICS COM 25056L103 389,437 -88,655 1,305 0.0001
2024-10-17 2024-03-31 13F/A-2 DESIGN THERAPEUTICS COM 25056L103 478,092 -65,389 -12.03 1,927 33.75 0.0002
2024-08-16 2024-03-31 13F/A-1 DESIGN THERAPEUTICS COM 25056L103 478,092 -65,389 1,927 0.0000
2024-05-15 2024-03-31 13F DESIGN THERAPEUTICS COM 25056L103 478,092 -65,389 1,927 0.0002
2024-08-16 2023-12-31 13F/A-1 DESIGN THERAPEUTICS COM 25056L103 543,481 183,223 50.86 1,440 69.41 0.0001
2024-02-13 2023-12-31 13F DESIGN THERAPEUTICS COM 25056L103 543,481 183,223 1,440 0.0001
2023-11-15 2023-09-30 13F DESIGN THERAPEUTICS COM 25056L103 360,258 169,490 88.85 850 -29.23 0.0001
2023-08-14 2023-06-30 13F DESIGN THERAPEUTICS COM 25056L103 190,768 121,391 174.97 1,202 200.25 0.0001
2023-05-15 2023-03-31 13F DESIGN THERAPEUTICS COM 25056L103 69,377 27,953 67.48 400 -5.88 0.0000
2023-02-14 2022-12-31 13F DESIGN THERAPEUTICS COM 25056L103 41,424 -17,511 -29.71 425 -56.85 0.0000
2022-11-14 2022-09-30 13F DESIGN THERAPEUTICS COM 25056L103 58,935 20,103 51.77 985 81.07 0.0001
2022-10-27 2022-06-30 13F/A-1 DESIGN THERAPEUTICS COM 25056L103 38,832 26,016 203.00 544 162.80 0.0001
2022-08-15 2022-06-30 13F DESIGN THERAPEUTICS COM 25056L103 38,832 26,016 544 0.0000
2022-10-27 2022-03-31 13F/A-1 DESIGN THERAPEUTICS COM 25056L103 12,816 -488 -3.67 207 -27.37 0.0000
2022-05-13 2022-03-31 13F DESIGN THERAPEUTICS COM 25056L103 12,816 -488 207 0.0000
2022-02-14 2021-12-31 13F DESIGN THERAPEUTICS COM 25056L103 13,304 5,900 79.69 285 163.89 0.0000
2021-11-15 2021-09-30 13F DESIGN THERAPEUTICS COM 25056L103 7,404 6,757 1,044.36 108 730.77 0.0000
2021-08-23 2021-06-30 13F/A-1 DESIGN THERAPEUTICS COM 25056L103 647 647 13 0.0000
2021-08-16 2021-06-30 13F DESIGN THERAPEUTICS COM 25056L103 647 647 13 0.0000
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.